Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing 'STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

2.5 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

Enzo Biochem has received 50.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote “Outperform” if you believe ENZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Miscellaneous

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

How has Enzo Biochem's stock been impacted by COVID-19 (Coronavirus)?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ENZ stock has decreased by 10.5% and is now trading at $2.56. View which stocks have been most impacted by Coronavirus.

When is Enzo Biochem's next earnings date?

How can I listen to Enzo Biochem's earnings call?

Enzo Biochem will be holding an earnings conference call on Monday, June 8th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) EPS for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a negative return on equity of 31.31% and a net margin of 1.92%. View Enzo Biochem's earnings history.

Has Enzo Biochem been receiving favorable news coverage?

Media stories about ENZ stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enzo Biochem earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutEnzo Biochem.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,860,000 shares, an increase of 10.1% from the April 30th total of 1,690,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is currently 1.6 days. Currently, 4.2% of the company's shares are sold short. View Enzo Biochem's Current Options Chain.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Nuveen Asset Management LLC, BlackRock Inc., State Street Corp, UBS Group AG, Two Sigma Advisers LP, Acadian Asset Management LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.56.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $121.75 million and generates $81.17 million in revenue each year. Enzo Biochem employs 460 workers across the globe.